
Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents
Keywords: MDR reversers; P-gp modulators; Piperazine derivatives; Chemosensitizers; Doxorubicin-resistant human erythroleukemia K562â¯cells (K562/DOX); Pirarubicin uptake; P-gp; P-glycoprotein; MRP1; Multidrug Resistance associated Protein 1; BCRP; Breast Cancer R